News

PNI provides technologies, services, and solutions to develop lipid nanoparticle genomic medicines, while Replicate Bioscience designs and delivers srRNA immunotherapies. Under the terms of the deal, PNI will

Tezspire has been recommended as an add-on therapy for these patients whose condition is not sufficiently controlled with high dose inhaled corticosteroids besides another medicinal product for maintenance

The plant-derived small molecule, tigilanol tiglate targets various solid tumours across multiple species. The drug is being developed as an intratumoural treatment for solid tumours. It has a

This study was undertaken in ~184 subjects, who were randomised 1:1 and received either a booster dose of the vaccine or a placebo, ~six months following the primary

The funding round was led by Enavate Sciences, a portfolio company created by Patient Square Capital. The round also saw participation of Gaingels, along with other undisclosed investors.

Applying Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology, the partnership intends to develop intravitreal AAV capsids matching a capsid profile defined by Roche. As per the

Under the two-year sponsored research alliance, the companies will work to identify new drug candidates that enable inhibition of two proteins, Bax and Bak. These proteins are integral

Under the terms of the deal, the company will be responsible for the supply of 2.5 million additional doses of liquid frozen Jynneos vaccines. The latest move follows

Discovered and developed by SK Biopharmaceuticals and SK life science, cenobamate is an anti-seizure medication (ASM). It is already approved and available in Europe and the US to treat